Lower start PSA - good. Higher PSA fall - good for Zytiga (abiraterone) pre-chemo in metastatic castrate resistant prostate cancer

[JimJimJimJim]

Jim Marshall (not a doctor) said ...

Zytiga (abiraterone) pre-chemo in metastatic castrate resistant prostate cancer: Lower start PSA - good. Higher PSA fall - good.

 

Zytiga is not yet approved pre-chemo in Australia. It is approved, but not yet available on the Pharmaceutical Benefits Scheme (PBS) in Australia (June 2013).

... end Jim

 

This abstract is only available for 24 hours for members to get an email.
After 24 hours the abstract will only be available through the link to the ASCO site below.

 

 

Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.

 

... 

Caution
This extract was published in association with the American Society of Clinical Oncology 2013 annual conference. Though the research behind it may have been excellent, your doctor cannot yet give much weight to it for a number of reasons, including:

• It is only an extract. The full paper may reveal information important for your treatment.
• The study has not yet had peer review - with doctors and researchers scrutinising the study closely for mistakes and limitations after it is published in a professional journal.
•  Your doctor may already be aware of a limitations of the findings because of their wider reading.

The link below is to a page or document that we do not control.
Parts of it may be wrong or misleading.
Check with your doctor if something interests you.
If it is temporarily or permanently unavailable, you may receive an error message.

 

Source URL: http://meetinglibrary.asco.org/content/109945-132